Piper Sandler Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $83.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target raised by stock analysts at Piper Sandler from $70.00 to $83.00 in a research report issued on Tuesday, The Fly reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s target price would indicate a potential upside of 12.68% from the company’s previous close.

A number of other analysts have also issued reports on the company. Citigroup raised their price target on Ultragenyx Pharmaceutical from $53.00 to $66.00 and gave the stock a “neutral” rating in a research note on Friday, May 8th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $61.00 price target for the company in a research report on Thursday, April 16th. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Friday, June 19th. Canaccord Genuity lifted their target price on Ultragenyx Pharmaceutical from $75.00 to $85.00 and gave the company a “buy” rating in a report on Friday, June 19th. Finally, Stifel Nicolaus upped their price target on Ultragenyx Pharmaceutical from $70.00 to $82.00 and gave the stock a “buy” rating in a research note on Monday, May 18th. Three equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $77.64.

RARE stock traded down $2.92 on Tuesday, reaching $73.66. The company had a trading volume of 375,300 shares, compared to its average volume of 577,534. The company’s fifty day moving average is $71.53 and its 200 day moving average is $57.31. The company has a market cap of $4.57 billion, a P/E ratio of -10.02 and a beta of 2.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.49 and a current ratio of 4.54. Ultragenyx Pharmaceutical has a 1 year low of $31.99 and a 1 year high of $79.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.23). The firm had revenue of $36.31 million during the quarter, compared to analyst estimates of $36.74 million. Ultragenyx Pharmaceutical had a negative net margin of 348.78% and a negative return on equity of 60.65%. The business’s quarterly revenue was up 99.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.82) EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical will post -6.43 earnings per share for the current year.

In related news, Director Matthew K. Fust sold 1,875 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $65.00, for a total transaction of $121,875.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Theodore Alan Huizenga sold 2,461 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, May 15th. The stock was sold at an average price of $71.00, for a total transaction of $174,731.00. Following the sale, the senior vice president now directly owns 18,719 shares in the company, valued at approximately $1,329,049. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,555 shares of company stock worth $1,942,395. Company insiders own 8.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 4.5% in the first quarter. Ameritas Investment Partners Inc. now owns 4,854 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 208 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Ultragenyx Pharmaceutical by 1.6% during the 1st quarter. Principal Financial Group Inc. now owns 16,024 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 246 shares during the last quarter. First Mercantile Trust Co. raised its position in shares of Ultragenyx Pharmaceutical by 14.5% in the 1st quarter. First Mercantile Trust Co. now owns 2,161 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 274 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of Ultragenyx Pharmaceutical by 0.6% during the 1st quarter. New York State Common Retirement Fund now owns 49,400 shares of the biopharmaceutical company’s stock valued at $2,195,000 after buying an additional 300 shares during the last quarter. Finally, RMB Capital Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 1.6% during the first quarter. RMB Capital Management LLC now owns 29,754 shares of the biopharmaceutical company’s stock worth $1,322,000 after buying an additional 476 shares in the last quarter. 99.91% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Further Reading: What Are Cryptocurrencies?

The Fly

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply